GH
Guardant Health, Inc. is a precision oncology company, which engages in provision of precision oncology testing and development services. It focuses performing blood tests, vast data sets, and advanced analytics to conquer cancer. The company was founded by Helmy Eltoukhy and AmirAli H. Talasaz in 2012 and is headquartered in Redwood City, CA.
Guardant Health Inc (GH) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B-); its weakest is Profitability (D+).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-08-05 | C+ (2.5) | B- (3.0) | D+ (1.7) | C (2.4) | C- (1.9) | C (2.3) |
| 2026-08-04 | C+ (2.5) | B- (3.0) | D+ (1.7) | C (2.4) | C- (1.9) | C (2.3) |
| 2026-08-03 | C+ (2.5) | C+ (2.6) | C (2.2) | C (2.4) | C- (2.0) | C (2.3) |
| 2026-08-02 | C+ (2.5) | C+ (2.6) | C (2.2) | C (2.4) | C- (1.9) | C (2.3) |
| 2024-03-31 | C+ (2.6) | B+ (3.5) | C+ (2.7) | A (4.2) | D+ (1.5) | B- (2.9) |